426c.Mod.Core-C4b adjuvanted With 3M-052-AF/Alum / National Institute of Allergy and Infectious Diseases - LARVOL DELTA

The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies (clinicaltrials.gov) - P1 | N=40 | Suspended | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting ➔ Suspended

Trial suspension • Human Immunodeficiency Virus • Infectious Disease • CD4

HVTN 316: Safety & Immunogenicity of 426c.Mod.Core-C4b Vaccine With 3M-052-AF+Alum in Infants Perinatally Exposed to HIV But Uninfected (clinicaltrials.gov) - P1 | N=22 | Not yet recruiting | Sponsor: HIV Vaccine Trials Network | Initiation date: Apr 2025 ➔ Oct 2025

Trial initiation date • Human Immunodeficiency Virus • Infectious Disease

HVTN 316: Comparing the Safety and Immunogenicity of 426c.Mod.Core-C4b Vaccine Adjuvanted with 3M-052-AF + Alum in Infants with Perinatal HIV Exposure Who Are Without HIV At Birth (clinicaltrials.gov) - P1 | N=22 | Not yet recruiting | Sponsor: HIV Vaccine Trials Network

New P1 trial • Human Immunodeficiency Virus • Infectious Disease

The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Human Immunodeficiency Virus • Infectious Disease • CD4

The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Combination therapy • New P1 trial • Human Immunodeficiency Virus • Infectious Disease • CD4